BKS Advisors LLC Acquires New Holdings in Teladoc Health Inc (TDOC)

BKS Advisors LLC acquired a new stake in shares of Teladoc Health Inc (NYSE:TDOC) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 13,935 shares of the health services provider’s stock, valued at approximately $1,203,000.

Several other institutional investors and hedge funds have also modified their holdings of TDOC. Bank of America Corp DE lifted its holdings in shares of Teladoc Health by 82.8% during the 2nd quarter. Bank of America Corp DE now owns 1,883,185 shares of the health services provider’s stock valued at $109,318,000 after purchasing an additional 853,076 shares during the last quarter. Summit Partners L P purchased a new stake in shares of Teladoc Health during the 2nd quarter valued at $37,772,000. Westwood Management Corp IL lifted its holdings in shares of Teladoc Health by 1,342.6% during the 2nd quarter. Westwood Management Corp IL now owns 585,700 shares of the health services provider’s stock valued at $34,000,000 after purchasing an additional 545,100 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Teladoc Health by 9.0% during the 2nd quarter. BlackRock Inc. now owns 5,318,850 shares of the health services provider’s stock valued at $308,759,000 after purchasing an additional 437,136 shares during the last quarter. Finally, OppenheimerFunds Inc. purchased a new stake in shares of Teladoc Health during the 2nd quarter valued at $20,163,000.

Several analysts have recently commented on TDOC shares. Berenberg Bank started coverage on Teladoc Health in a report on Monday, July 9th. They set a “buy” rating and a $72.00 price objective for the company. KeyCorp increased their price objective on Teladoc Health from $50.00 to $70.00 and gave the company an “overweight” rating in a report on Monday, July 9th. Jefferies Financial Group set a $74.00 price objective on Teladoc Health and gave the company a “buy” rating in a report on Wednesday, July 11th. Citigroup raised their target price on Teladoc Health to $80.00 and gave the stock a “buy” rating in a research note on Thursday, July 19th. Finally, Canaccord Genuity restated a “buy” rating and issued a $70.00 target price (up previously from $63.00) on shares of Teladoc Health in a research note on Wednesday, July 25th. One analyst has rated the stock with a sell rating, four have given a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $81.95.



In other Teladoc Health news, CEO Jason N. Gorevic sold 25,000 shares of Teladoc Health stock in a transaction dated Thursday, August 16th. The stock was sold at an average price of $71.66, for a total transaction of $1,791,500.00. Following the completion of the transaction, the chief executive officer now owns 561,184 shares in the company, valued at approximately $40,214,445.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Mark Hirschhorn sold 35,000 shares of Teladoc Health stock in a transaction dated Tuesday, September 25th. The shares were sold at an average price of $80.42, for a total value of $2,814,700.00. Following the transaction, the vice president now owns 10,000 shares of the company’s stock, valued at approximately $804,200. The disclosure for this sale can be found here. Insiders have sold a total of 156,706 shares of company stock valued at $11,710,929 in the last quarter. Company insiders own 3.95% of the company’s stock.

TDOC stock traded down $2.26 during midday trading on Friday, reaching $63.70. The stock had a trading volume of 1,151,743 shares, compared to its average volume of 1,280,031. The firm has a market capitalization of $4.81 billion, a price-to-earnings ratio of -38.61 and a beta of 0.57. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.14 and a quick ratio of 3.14. Teladoc Health Inc has a 52-week low of $27.30 and a 52-week high of $89.05.

Teladoc Health (NYSE:TDOC) last issued its earnings results on Wednesday, August 1st. The health services provider reported ($0.37) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.01. The company had revenue of $94.60 million during the quarter, compared to analyst estimates of $91.56 million. Teladoc Health had a negative return on equity of 19.10% and a negative net margin of 37.78%. The firm’s quarterly revenue was up 112.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.28) EPS. As a group, equities research analysts expect that Teladoc Health Inc will post -1.49 earnings per share for the current year.

Teladoc Health Profile

Teladoc Health, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Featured Story: Analyst Ratings

Institutional Ownership by Quarter for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply